<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03209128</url>
  </required_header>
  <id_info>
    <org_study_id>IPC</org_study_id>
    <nct_id>NCT03209128</nct_id>
  </id_info>
  <brief_title>Cerebral Prophylactic Irradiation With Saving Hippocampus and Amygdala</brief_title>
  <acronym>IPC</acronym>
  <official_title>Savings of Hippocampus and Amygdala by Archetherapy in Cerebral Prophylactic Irradiation in Patients With Limited and / or Extended, Responsive or Stable Small Cell Lung Cancer (SCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse, Luxembourg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Francois Baclesse, Luxembourg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hippocampus and amygdala are parts of the brain involved in the recognition of emotions,
      memories, memory, language ... It is therefore very important to protect them during
      irradiation of the brain.

      The aim of this study is to evaluate cerebral irradiation with saving hippocampus and
      amygdala protects these brain functions in patients with small cell lung cancer (SCLC)
      Radiotherapy of the brain
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>until 18 months after inclusion of patient</time_frame>
    <description>Evaluate the cognitive function with Wechsler Memory Scale IV (WMS-IV) test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary effects according the CTCAE v.4 criteria</measure>
    <time_frame>until 18 months after inclusion of patient</time_frame>
    <description>Evaluate the toxicity according the CTCAE v.4 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appearance of brain metastases and their location</measure>
    <time_frame>until 18 months after inclusion of patient</time_frame>
    <description>Evaluate the brain control with brain MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL) of patients</measure>
    <time_frame>until 18 months after inclusion of patient</time_frame>
    <description>Evaluate QOL with FACT-BR test (Functional Assessment of Cancer Therapy-Brain)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Irradiation prophyllactique cérébrale</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Irradiation prophyllactique cérébrale</intervention_name>
    <description>Irradiation prophyllactique cérébrale</description>
    <arm_group_label>Irradiation prophyllactique cérébrale</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with limited SCLC histologically proven to be responders or stable to
        radiochemotherapy or patients with histologically proven extended SCLC responding to
        chemotherapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 years of age

          -  Patients with a limited SCLC demonstrated histologically responsive or stable to
             radiochemotherapy or patients with a histologically proven extended SCLC responding to
             chemotherapy.

          -  WHO Performance Index 0-1 and / or Karnovsky Index&gt; 70

          -  Possibility of long-term monitoring

        Exclusion Criteria:

          -  Concomitant chemotherapy

          -  Impossibility of performing an MRI or CT without injection

          -  Presence of cerebral metastases

          -  History of cerebral irradiation at any time

          -  Patient suffering from severe collagenosis

          -  Patient with cognitive disorders with MMSE score &lt;24
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bérangère Frédérick, MD</last_name>
    <phone>00352571167200</phone>
    <email>berangere.frederick@baclesse.lu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charlotte Lieunard</last_name>
    <phone>00352571167200</phone>
    <email>charlotte.lieunard@baclesse.lu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Esch Sur Alzette</city>
        <zip>4005</zip>
        <country>Luxembourg</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Luxembourg</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2017</study_first_submitted>
  <study_first_submitted_qc>July 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2017</study_first_posted>
  <last_update_submitted>July 3, 2017</last_update_submitted>
  <last_update_submitted_qc>July 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

